Important Notice:
the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 13th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

GLOBAL PAYMENTS INC. (GPN) REPORT OVERVIEW

Global Payments' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Global Payments reported revenue of $857.67MM vs $1,038.91MM (down 17.44%) and analysts estimated basic earnings per share $1.12 vs $0.72 (up 55.56%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.07. The estimated EPS forecast for the next fiscal year is $6.72 and is expected to report on February 12th, 2020.

For the three months ended September 30th, 2018 vs September 30th, 2017, Tableau Software reported revenue of $290.58MM vs $214.92MM (up 35.21%) and analysts estimated basic earnings per share -$0.26 vs -$0.59. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Tableau Software reported revenue of $877.06MM vs $826.94MM (up 6.06%) and analysts estimated basic earnings per share -$2.35 vs -$1.92. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.73. The estimated EPS forecast for the next fiscal year is -$0.55 and is expected to report on February 4th, 2020.

For the three months ended October 31st, 2018 vs October 31st, 2017, Summit Therapeutics reported revenue of $0.88MM vs $2.29MM (down 61.83%) and analysts estimated basic earnings per share -$0.65 vs -$0.20. For the twelve months ended January 31st, 2018 vs January 31st, 2017, Summit Therapeutics reported revenue of $33.08MM vs $3.08MM (up 973.16%) and analysts estimated basic earnings per share -$0.70 vs -$2.32. Analysts expect earnings to be released on April 10th, 2019. The report will be for the fiscal period ending January 31st, 2019. Reported EPS for the same quarter last year was -$1.15. The estimated EPS forecast for the next fiscal year is -$1.42 and is expected to report on April 10th, 2019.

For the three months ended October 31st, 2018 vs October 31st, 2017, Urstadt Biddle Properties reported revenue of $32.54MM vs $32.62MM (down 0.25%) and analysts estimated basic earnings per share $0.13 vs $0.01 (up 1,200.00%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Urstadt Biddle Properties reported revenue of $135.35MM vs $123.56MM (up 9.54%) and analysts estimated basic earnings per share $0.66 vs $0.90 (down 26.67%). Analysts expect earnings to be released on March 8th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $1.45 and is expected to report on December 13th, 2019.

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that’s ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.